Patents by Inventor Yizong Zhou

Yizong Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
    Publication number: 20210155606
    Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 8, 2021
    Publication date: May 27, 2021
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Aminopyridine derivatives and their use as selective ALK-2 inhibitors
    Patent number: 10947218
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: March 16, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
    Publication number: 20200299265
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 24, 2020
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Aminopyridine derivatives and their use as selective ALK-2 inhibitors
    Patent number: 10710980
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Novartis AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
    Publication number: 20190161474
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: July 18, 2017
    Publication date: May 30, 2019
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS
    Publication number: 20150166563
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 18, 2015
    Applicant: NOVARTIS AG
    Inventors: Sejal Patel, Justin Mao, Qian Liu, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
  • Cyclic bridgehead ether DGAT1 inhibitors
    Patent number: 8993619
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Sejal Patel, Justin Mao, Qian Liu, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
  • CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS
    Publication number: 20130289058
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Application
    Filed: April 26, 2013
    Publication date: October 31, 2013
    Inventors: Sejal Patel, Justin Mao, Qian Lui, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai